Armata Pharmaceuticals published a study detailing the structure of phage P7-1, part of their AP-PA02 cocktail targeting Pseudomonas aeruginosa infections in cystic fibrosis and bronchiectasis patients. Using advanced cryo-electron microscopy, the research uncovered how P7-1's unique tail fibers contribute to its stability and infection mechanism. This insight supports Armata's development of phage therapies as alternatives to antibiotics, with AP-PA02 showing promise in Phase 2 trials. The findings pave the way for engineering more effective and stable phage treatments against resistant bacterial infections.
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
17 Education & Technology Group Inc. reported a strong first quarter for 2026 with net revenues soaring 359% year-over-year to RMB99.5 million, driven by its AI-powered personalized learning app Yiqi Aixue. The company improved its gross margin to 61...
The Schall Law Firm is investigating Simulations Plus, Inc. for potentially issuing false or misleading statements and failing to disclose important information to investors. This probe could impact shareholders who may have suffered losses due to th...
Japan's exports in May rose 17% year on year, the fastest growth since November 2022, driven by a 61.2% surge in semiconductor exports fueled by strong demand for AI technology and a 16.4% increase in car shipments. Imports also rose 12.5%, the highe...
Brodsky & Smith LLC has announced investigations into the merger agreements of Simulations Plus, Roku, TruBridge, and Organon. The investigations focus on whether the respective company boards breached their fiduciary duties by not ensuring a fair pr...
